Ten post jest także dostępny w języku: polski
PolTREG will debut on the main market of the Warsaw Stock Exchange (WSE) today, Tuesday, 23 November. The funds raised through the share issue will enable the company to develop key strategic objectives, such as clinical trials of cell therapies for the treatment of type 1 diabetes.
The debut on the WSE was preceded by the allotment of a maximum of 1,332,414 new shares in a public offering valued at approximately PLN 100m gross. The reduction rate in the retail tranche reached 24.22%.
PolTREG, which is a global pioneer in cellular therapies, will use the proceeds from the issue of new shares, among others, to finance clinical trials of this type of therapy for the treatment of type 1 diabetes and multiple sclerosis. In addition, the company will develop the Treg 2.0. platform, which deals with antigen-specific Tregs and CAR-TREGs. In this project, the company will collaborate with AZTherapies, which is one of the leaders in this type of solution. The share issue will also help finance the construction of a research and development centre and a new production laboratory in Gdansk for the commercial production of TREGS preparations.
PolTREG uses T-regulatory T cells (TREGS) in its therapies, which allow it to offer solutions in the field of autoimmunity. Advanced clinical trials also give patients struggling with type 1 diabetes or multiple sclerosis a chance to receive an effective drug in the future. It is worth mentioning that PolTREG conducted the world’s first administration of TREG preparation in humans.